Kiniksa Pharmaceuticals International (KNSA) vs Phibro Animal Health (PAHC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kiniksa Pharmaceuticals International (KNSA) has outperformed Phibro Animal Health (PAHC) over the past year, gaining 105.6% versus a gain of 0.8%. Over five years, KNSA leads with a +587.8% price change compared with +71.6% for PAHC. Kiniksa Pharmaceuticals International is the larger company by market cap ($6.23 billion vs $1.58 billion), about 4.0 times the size.
On valuation, Phibro Animal Health trades at a lower forward P/E (10.1x vs 49.4x for Kiniksa Pharmaceuticals International). Phibro Animal Health pays a dividend yielding 1.24%, while Kiniksa Pharmaceuticals International does not currently pay one. Kiniksa Pharmaceuticals International converts more of its revenue into profit, with a net margin of 8.7% versus 6.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KNSA | PAHC |
|---|---|---|
| Share price | $79.83 | $38.82 |
| Market cap | $6.23B | $1.58B |
| 1-day change | +1.37% | +3.80% |
| YTD return | +90.91% | +0.11% |
| 1-year return | +105.56% | +0.78% |
| 5-year return | +587.77% | +71.56% |
| P/E ratio (TTM) | 80.64 | 15.98 |
| Forward P/E | 49.35 | 10.10 |
| EPS (TTM) | $0.99 | $2.43 |
| Dividend yield | 0.00% | 1.24% |
| Annual dividend | $0.00 | $0.48 |
| Revenue (latest FY) | $677.56M | $1.52B |
| Revenue growth (YoY) | +60.09% | +17.12% |
| Net income (latest FY) | $59.01M | $99.72M |
| Gross margin | 88.54% | 33.76% |
| Operating margin | 11.40% | 12.81% |
| Net margin | 8.71% | 6.57% |
| 52-week high | $82.94 | $60.08 |
| 52-week low | $35.20 | $28.25 |
| Distance from 52-week high | -3.75% | -35.39% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +22.76% | +13.34% |
| Average volume | 573.74K | 236.19K |
| Shares outstanding | 48.29M | 21.11M |
| Employees | 366 | 2,605 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Kiniksa Pharmaceuticals International is about 4.0 times larger than Phibro Animal Health by market value ($6.23B vs $1.58B).
- KNSA has outperformed PAHC by 104.8 percentage points over the past year.
- Kiniksa Pharmaceuticals International trades at a higher earnings multiple (80.6x vs 16.0x trailing P/E).
- Phibro Animal Health offers a meaningfully higher dividend yield (1.24% vs 0.00%).
- Kiniksa Pharmaceuticals International grew revenue faster in its latest fiscal year (+60.09% vs +17.12%).
About Kiniksa Pharmaceuticals International
KNSA stock →Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees
About Phibro Animal Health
PAHC stock →Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,605 employees
KNSA vs PAHC FAQ
Which is bigger, Kiniksa Pharmaceuticals International or Phibro Animal Health?
Kiniksa Pharmaceuticals International (KNSA) is larger, with a market capitalization of $6.23B compared with $1.58B for Phibro Animal Health (PAHC).
Which stock has performed better over the past year, KNSA or PAHC?
KNSA returned +105.56% over the past 12 months, compared with +0.78% for PAHC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, KNSA or PAHC?
PAHC has the lower trailing P/E at 16.0, versus 80.6 for KNSA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Kiniksa Pharmaceuticals International or Phibro Animal Health?
Phibro Animal Health pays a dividend yielding 1.24%, while Kiniksa Pharmaceuticals International does not currently pay a regular dividend.
Are Kiniksa Pharmaceuticals International and Phibro Animal Health in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.